How we made the decision

Exceptionally, significant new evidence may mean an update of a guideline is agreed before the next scheduled check of the need for updating. The evidence might be a single piece of evidence, an accumulation of evidence or other published NICE guidance. We based the decision on an exceptional surveillance review of corticosteroid treatment for alcohol‑related hepatitis to consider the impact of the NIHR‑funded STOPAH trial on the recommendations for corticosteroid treatment. Stakeholders informed us that the results of the STOPAH trial had published and felt that this new evidence was significant and could have an impact on guideline recommendations.

For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual'.

Previous surveillance update decisions for alcohol‑use disorders (2010) NICE guideline CG100 are on our website.

New evidence

We found 4 new studies in a search for randomised controlled trials and systematic reviews relevant to corticosteroid treatment for alcohol‑related hepatitis published between 1 November 2014 and 21 January 2016.

Evidence identified in previous surveillance 2 and 4 years after publication of the guideline was also considered. This included 7 studies identified by search.

From all sources, 11 studies were considered to be relevant to corticosteroid treatment for alcohol‑related hepatitis.

See appendix A: decision matrix for summaries and references for all new evidence considered.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline.

Views of stakeholders

Stakeholders are consulted only if we decide not to update the guideline following checks at 4 and 8 years after publication. Because this was an exceptional surveillance review to consider the impact of the STOPAH trial on the recommendations on corticosteroid treatment for alcohol-related hepatitis, and the decision was to update, we did not consult on the decision.

See ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual' for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett
Associate Director

Philip Alderson
Consultant Clinical Adviser

Emma McFarlane
Technical Adviser

The NICE project team would like to thank the topic experts who participated in the surveillance exceptional review.


This page was last updated: